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CASE REPORT
A 63-year-old female diagnosed with relapsed multiple myeloma visited our hospital complaining of a persistent
cough. Since July 2006, she had been taking 100 mg thalidomide daily and gradually developed shortness of
breath and a persistent dry cough. A chest X-ray and computed tomography showed ground glass opacities in
both lungs. An open lung biopsy of the right middle lobe under general anesthesia revealed chronic peribronchial
inflammation, mild interstitial fibrosis, and intra-alveolar macrophage infiltration, with some hemosiderin features,
compatible with non-specific interstitial pneumonia (NSIP). After discontinuing the thalidomide, the patient's
symptoms did not deteriorate, although the radiographs did not improve. The patient is alive and well with regular
outpatient follow-up without progression of the NSIP. (Korean J Intern Med 2010;25:447-449)
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INTRODUCTION
Thalidomide has anti-angiogenic and immunomodul-
atory effects. Recently, it has been used increasingly
worldwide as a first-line and salvage therapy for multiple
myeloma. Pulmonary adverse effects of thalidomide are
rare, although the use of thalidomide alone or combinat-
ion with steroids was recently reported to cause pulm-
onary embolism and “bronchiolitis obliterans with
organizing pneumonia.” Because cases of drug-induced
non-specific interstitial pneumonia (NSIP) are rare, we
report this case of NSIP that occurred in a patient with
multiple myeloma.
CASE REPORT
A 63-year-old female visited our hospital complaining of
shortness of breath and a persistent dry cough. She had
been diagnosed with multiple myeloma in September
1998 and achieved complete remission with first-line
cyclophosphamide and prednisolone treatment. In March
2004, elevated M-protein was detected on serum electroph-
oresis, and vincristine, adriamycin, and dexamethasone
chemotherapy was administered, which partially relieved
her symptoms. In January 2005, disease progression was
observed and combined bortezomib and dexamethasone
chemotherapy was given, resulting in complete remission.
In June 2006, elevated M-protein was again detected on
serum electrophoresis, so she was given 100 mg thalid-
omide daily beginning in July 2006. Beginning in
December 2006, the patient reported a persistent dry
cough and dyspnea on exertion.
Coarse breath sounds were heard in both lungs.
Pulmonary function tests revealed a restrictive ventilatory
defect (FVC, 1.13 L, 50.4% of normal predicted value;
FEV1, 1.06 L, 56.8% of normal predicted value; normal
FEV1/FVC, 88.3%). Her arterial blood gas analysis showed
hypoxia on room air (pH, 7.37; PO2, 59 mmHg; PCO2, 49mmHg; O2saturation, 90%).
Gram staining and special stains of sputum for acid-fast
bacilli, Pneumocystis carinii, and fungi were negative.
Routine cultures for bacteria, fungi, and mycobacteria
showed no growth. The chest X-ray showed progressive
infiltration of both lung fields. Computed tomography
(CT) of the lungs revealed new bilateral patchy ground-
glass opacities, suggestive of interstitial pneumonitis and
underlying bronchiectasis (Fig. 1).
Extrathoracic echocardiography showed normal left
ventricular contractility with an unaltered ejection fraction
and the cardiac enzymes were normal. Chest CT angio-
graphy showed no evidence of pulmonary artery embolism.
Fiberoptic bronchoscopy revealed no evidence of an
endobronchial lesion. No malignant cells were found in
the bronchoalveolar lavage fluid (BALF).
Gram stains, special analysis, and cell cultures of BALF
and sputum following fiberoptic bronchoscopy were
negative for bacteria, acid-fast bacilli, fungi, and P carinii. The
results of a polymerase chain reaction study and viral culture
of BALF were negative for cytomegalovirus. A bronchosc-
opyguided transbronchial lung biopsy was performed and
showed non-specific chronic inflammation.
The use of thalidomide was suspended for 1 month, and
no further deterioration of her symptoms was detected. In
February 2007, the use of thalidomide was resumed. Two
months later, the chest X-ray and CT showed progression
of the diffuse ground-glass appearance in both lungs, and
her dyspnea on exertion had worsened. In April 2006, to
assess causality, an open lung biopsy of the right middle
lobe was performed under general anesthesia. This
showed chronic peribronchial inflammation, mild
interstitial fibrosis, and intra-alveolar infiltration, with
some hemosiderin features, compatible with NSIP (Fig.
2). Subsequently, the thalidomide was stopped
completely, and the chest X-ray and CT 1 month later
showed slight improvement in the bilateral pulmonary
lesions, along with some symptom improvement. She is
alive and doing well on regular outpatient follow-up with
no progression of the NSIP after discontinuing
thalidomide.
DISCUSSION
Thalidomide was developed as an antiemetic drug in the
1950s and found to induce congenital anomalies, so its use
was banned. Since 1998, based on the fact that this drug
exerts anti-angiogenic and immunomodulatory effects, its
use as a standard therapeutic agent for multiple myeloma
has increased [1]. Common reported side effects of
thalidomide include constipation, vertigo, edema, fatigue,
emotional change, and peripheral neuropathy [2].
Drug-induced interstitial pneumonia has been reported
with approximately 20 types of drug, including various
antibiotic, chemotherapeutic, and anti-inflammatory
agents [3]. In most cases, the symptoms of drug-induced
interstitial pneumonia develop within a few weeks to a few
months after drug administration, and there is rapid
symptom improvement after discontinuing the drug. To
diagnose drug-induced interstitial pneumonia, it is
important to rule out other infections and malignant
tumors and to suspect that the symptoms are induced by
specific drugs.
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Figure 1. Computed tomography of the lung showed new
bilateral patchy ground-glass opacities and underlying
bronchiectasis.
Figure 2. The open lung biopsy revealed chronic peribronchial
inflammation, mild interstitial fibrosis, and intra-alveolar
infiltration with some hemosiderin features, consistent with
non-specific interstitial pneumonia (H&E, × 200).
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W 1736 : L-223Pulmonary embolism is the most frequent respiratory
side effect of thalidomide, while interstitial pneumonia is
very rare [4-6]. A case report described a pattern of right-
side heart failure and concomitant dyspnea, with features
of interstitial pneumonia on a chest X-ray [7]. On
discontinuing the thalidomide, this patient's symptoms
improved; however, because no chest CT or bronchoscopic
findings were described in this case, it could not be
concluded that the pulmonary side effects were definitely
caused by thalidomide. Another case report describes
pulmonary toxicity that occurred during treatment with
docetaxel and thalidomide in three patients with
hormone-refractory prostate cancer [8]. One of the
patients shows interstitial pneumonia, although it was
determined that the main cause of the pulmonary toxicity
in this patient was more likely docetaxel than thalidomide.
In 2005, a case of typical interstitial pneumonia induced
by thalidomide was reported [9]. Chest CT showed diffuse
interstitial infiltration and cultures of BALF and sputum
obtained by bronchoscopy were negative. After discont-
inuing the thalidomide, the patient's symptoms and chest
radiographs improved, although the results were not
validated histologically by a biopsy.
Thalidomide-induced interstitial pneumonia should be
suspected in patients who develop dyspnea, cough, and
fever after taking thalidomide, without a definite cause,
when the chest X-ray shows a diffuse pulmonary
infiltration [4-6,9].
Our patient had an ongoing cough and dyspnea on
exertion after taking thalidomide, and pulmonary
infection, malignant tumor, and lung involvement of
multiple myeloma were excluded through various tests.
We diagnosed this case as NSIP, based on an open lung
biopsy, and thalidomide was suspected to be cause. The
drug was discontinued, and subsequently her symptoms
improved.
When patients taking thalidomide have persistent
respiratory symptoms without a definite cause, drug-
induced interstitial pneumonia should be considered,
although rare, and appropriate examinations and
management of this disease should be considered.
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